亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease

医学 乌斯特基努马 克罗恩病 内科学 维持疗法 置信区间 胃肠病学 克罗恩病 银屑病面积及严重程度指数 随机对照试验 疾病严重程度 临床试验 银屑病 外科 疾病 免疫学 化疗 阿达木单抗
作者
Marla Dubinsky,Christopher Ma,Jenny Griffith,Marjorie Crowell,Ezequiel Neimark,Kristina Kligys,Tom O’Connell
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
卷期号:40 (9): 3896-3911
标识
DOI:10.1007/s12325-023-02546-6
摘要

Risankizumab (RZB) and ustekinumab (UST), interleukin (IL)-23 and IL-12/23 inhibitors, respectively, are approved treatments for moderately to severely active Crohn’s disease (CD); direct comparison between the two is ongoing. We indirectly compared efficacy of RZB versus UST using data from phase 3 trials (RZB: NCT03104413; NCT03105128; NCT03105102; UST: NCT01369329; NCT01369342; NCT01369355). Matching-adjusted indirect comparison was conducted using individual patient-level data from RZB trials and published aggregated data from UST trials. During induction, patients received RZB 600 mg intravenous (IV) at weeks 0, 4, and 8 or a single dose of UST 6 mg/kg IV at week 0. During maintenance, patients received RZB 180 or 360 mg subcutaneous (SC) or UST 90 mg SC every 8 or 12 weeks to 52 weeks. Outcomes included proportion of patients achieving Crohn’s Disease Activity Index (CDAI) response (decrease of ≥ 100 points or total score < 150) or remission (CDAI ≤ 150) and endoscopic improvement (measured by the Simple Endoscopic Score in CD [SES-CD]; response, ≥ 50% reduction from baseline; remission, SES-CD ≤ 2) following induction/baseline. Higher proportions of patients achieved clinical and endoscopic outcomes with RZB vs. UST induction treatment, resulting in significantly (p ≤ 0.05) greater percent differences (95% confidence intervals) between groups for CDAI remission (15% [5%, 25%]) and endoscopic response (26% [13%, 40%]) and remission (9% [0%, 19%]). Following maintenance, rates of CDAI remission were similar (range − 0.3% to − 5.0%) for RZB vs. UST. Differences for endoscopic response and remission ranged from 9.3% to 27.7% and 11.6% to 12.5%, respectively; differences were significant (p < 0.05) for endoscopic response for both doses of RZB compared to UST 12-week dosing. This indirect comparison demonstrated higher rates of clinical and endoscopic outcomes during induction for RZB compared to UST; CDAI remission following maintenance was comparable. Direct comparisons of RZB and UST are warranted to validate these findings. Using individual patient-level data from risankizumab and aggregated data from ustekinumab phase 3 Crohn’s disease trials, we indirectly compared efficacy of risankizumab and ustekinumab to determine whether rates of improvement in disease symptoms (clinical) and endoscopic outcomes differed between treatments. Findings showed that clinical and endoscopic outcomes were more frequently achieved for patients receiving risankizumab versus ustekinumab after induction, while most maintenance outcomes were comparable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
啦啦啦发布了新的文献求助30
2秒前
3秒前
典雅沛柔完成签到 ,获得积分10
3秒前
3秒前
3秒前
CAOHOU的应助被科研通管家采纳,获得10
4秒前
CipherSage的应助被科研通管家采纳,获得10
4秒前
Hu6868完成签到,获得积分20
4秒前
郭浩瑞发布了新的文献求助10
5秒前
机智的白卉的应助被令狐大侠采纳,获得10
6秒前
科研通AI6.3的应助被令狐大侠采纳,获得30
6秒前
科研通AI65的应助被令狐大侠采纳,获得10
6秒前
Maestro_S的应助被令狐大侠采纳,获得10
6秒前
深情安青的应助被令狐大侠采纳,获得10
6秒前
alex的应助被令狐大侠采纳,获得10
7秒前
CodeCraft的应助被令狐大侠采纳,获得30
7秒前
Maestro_S的应助被令狐大侠采纳,获得30
7秒前
Maestro_S的应助被令狐大侠采纳,获得30
7秒前
DW的应助被令狐大侠采纳,获得10
7秒前
8秒前
8秒前
13秒前
美满惜雪发布了新的文献求助10
16秒前
拉长的映波完成签到,获得积分10
16秒前
huang完成签到 ,获得积分10
16秒前
臭臭完成签到,获得积分10
21秒前
香蕉觅云的应助被郭浩瑞采纳,获得10
27秒前
YIMISS完成签到,获得积分10
27秒前
Gloria完成签到 ,获得积分10
33秒前
慕青的应助被YIMISS采纳,获得10
36秒前
春日桑完成签到 ,获得积分10
37秒前
会撒娇的思萱完成签到,获得积分10
42秒前
43秒前
43秒前
siri发布了新的文献求助10
48秒前
mmyhn发布了新的文献求助10
49秒前
健康的怜菡完成签到,获得积分10
57秒前
臭臭发布了新的文献求助10
57秒前
u114768完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185000
求助须知:如何正确求助?哪些是违规求助? 9573966
关于积分的说明 21833855
捐赠科研通 7782482
什么是DOI,文献DOI怎么找? 3434468
关于科研通互助平台的介绍 2558673
邀请新用户注册赠送积分活动 2481178